Clinical Research Directory
Browse clinical research sites, groups, and studies.
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
Sponsor: Peking University First Hospital
Summary
Along with aging population, cancer incidence and mortality are increasing. However, despite advances in oncology and surgery, long-term survival of cancer patients is far from optimal. Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine reduces delirium and some non-delirium complications after surgery. In long-term follow-up studies of older patients who, for other reasons, were randomized to receive either dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was associated with improved long-term survival. This multicenter randomized trial aims to investigate the effect of perioperative dexmedetomidine on long-term outcomes in older patients undergoing cancer surgery.
Official title: Impact of Perioperative Dexmedetomidine on Long-term Survival in Older Patients After Cancer Surgery: a Multicenter Randomized Trial
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
4532
Start Date
2023-09-12
Completion Date
2028-10
Last Updated
2025-07-31
Healthy Volunteers
No
Interventions
Dexmedetomidine
A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Placebo
Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Locations (39)
The First Affiliated Hospital of China University of Science and Technology
Hefei, Anhui, China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, Anhui, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Tsinghua University Yuquan Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Army Medical University (Southwest Hospital)
Chongqing, Chongqing Municipality, China
Fujian Provincial Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Jinjiang City Hospital (Shanghai Sixth People's Hospital, Fujian Hospital)
Jinjiang, Fujian, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Tangshan Workers' Hospital
Tangshan, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Xiangya Hospital Central South university
Changsha, Hunan, China
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China
Nanjing General Hospital of Nanjing Military Region
Nanjing, Jiangsu, China
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Bethune First Hospital Of Jilin University
Changchun, Jilin, China
General hospital of eastern theater command
Nanjing, Nanjing, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China
Xijing Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China
Shandong Provincial Hospital Heze Hospital
Heze, Shandong, China
Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China